drug discovery alert (techvision) - frost & sullivan · to achieve an in-depth understanding...

Drug Discovery Alert (TechVision)

Novel Drug Delivery Systems in the Spotlight

D951-TV

April 08, 2016

2 D951-TV

Section Slide Number

Trend Overview 3

Novel Drug Delivery Systems (NDDS) in the Spotlight 4

Technology Profiles in Drug Delivery Systems 5

Pioneering Digital Health and Smart Drug Delivery Systems

BIOCORP 6

Natural Monodisperse Phytoglycogen Nanomaterials for Advanced Drug Delivery

Glysantis, Inc. 7

Facilitating the Transport of Drugs and Imaging Agents via Molecular Vectors

VECT-HORUS 8

Microneedle Pill with Hollow Needles

Massachusetts Institute of Technology (MIT) – Massachusetts General Hospital (MGH) 9

New Liposomal Vesicles to Help Treat Coronary Artery Disease

The University of Basel 10

Biocompatible Targeted Cancer Therapy

Keystone Nano, Inc. 11

Nanoparticle Based Technology to Improve Drug Bioavailability

Camurus AB 12

Appendix 13

Patent Analysis 14

Industry Interactions 17

Contents

3 D951-TV

Trend Overview

4

The Novel Drug Delivery Systems (NDDS) Landscape

Why NDDS became a key concept in pharma development

Worldwide societal trends

Demographic and healthcare policy changes have

increased the complexity in the pharmaceutical and medical

device industries over the past five years. The aging

population, growing middle class, and rising disease burden

with chronic diseases, such as diabetes and cancer and

monitoring of autoimmune disorders therapeutics, and

metabolic diseases, among many others, represent just a

few issues that need to be addressed urgently.

xx

Value-based care concept

Moving toward a value-based care concept

of medicine, which strives for cost- and time-

efficient tools and digital instruments,

healthcare providers are re-shaping

healthcare delivery care models. The overall

structure of the industry, including the long

expedition from innovation to

commercialization, turns market access into

a challenging mission. However, with the

advent of digital technologies across a broad

spectrum of industries, users are becoming

confident in the use of digital equipment and

connected health notions. This can drive

adoption of novel technologies.

Self-administration trend

Devices need to be designed to prevent or

reduce user errors and patient data need

to be protected taking advantage of

connected health solutions and mobile

health applications. Therefore, these

challenges can be turned into huge

opportunities thanks to the greater

integration between informatics

applications and drug delivery and

administration devices, especially meeting

the need for medication adherence,

controlled release, and self-administration,

among others.

Shift toward biologics

In personalized medicine, the rules of the game are

changing in pharmaceutical development and

manufacturing activities, ranging from small molecules to

biologic drug products. The formulation of these complex

macromolecules is significantly more challenging than

their small-molecule counterparts.

Drug Delivery Systems A Brief Overview

5 D951-TV

Technology Profiles

6

Technology

Readiness Level

Biocorp is

open to

collaborations

with leading

medtech and

pharmatech

companies,

hospitals, and

institutes.

1 2 3

4 5 6

7 8 9

Wide-scale Adoption

The critical unmet need is the lack of contact and

interfacing between the patient and clinicians during

homecare treatment. Companies need to develop

new technologies in sync with equipment used

commonly, such as smartphones and tablets.

Biocorp’s ultimate goal is to increase the level of

treatment adherence of the patients and their overall

comfort.

Market Opportunity

Biocorp has invested in drug delivery

devices, more specifically, smart drug

delivery devices, convinced that the

healthcare system is changing very rapidly

and pharmaceutical companies need to

provide new solutions to their patients for

long term, chronic/debilitating diseases. The

company promptly understood the significant

market opportunity in this regard.

Vertically integrated connected health technology platform

to enhance drug delivery systems. BIOCORP is focused on

the development of innovative medical devices and drug

delivery systems. The platforms are based on three main

units: medical devices manufacturing, research and

development, and informatics technology.

Technology Profile

Aiming to achieve an in-depth understanding of customers’ real

needs, Biocorp works very closely with pharma companies

developing devices up to the functional prototype phase.

Customization programs and collaborative projects with large

companies are strategies followed by Biocorp to bring innovative

solutions to the industry.

Innovation Attributes

Biocorp is focused on therapeutic areas with major unmet

needs, thus contributing more efficient medical devices

from a holistic perspective. Biocorp develops no less than

two products per year on average, which constitutes a

significant milestone in the medical device sector. The

company’s vision is to connect existing medical devices

through novel sensors and data acquisition technologies to

gather precious information.

Competing Aspects

Biocorp’s strategy is to be the first to innovate, not follow. The

very first step for initiating a new project is to understand the

needs of patients and clinicians and translate these needs into

technical solutions. Biocorp is open to any collaborations with

medtech companies and healthcare centers and facilities to

deliver the best solutions for patients

Market Entry Strategies

D951-TV

Technology Convergence

Biocorp hopes that all the devices will be

connected with smartphones, tablets, and

other IT tools to keep track of treatment of

patients in real time and provide

information. In the oncology and

immunology therapeutic areas, there is a

need to shift from inpatient to outpatient

care protocols.

Impact & Opportunities

Pioneering Digital Health and Smart Drug Delivery Systems BIOCORP

7

Technology

Readiness Level

NanoGlys is

available for early

stage licensing

and partnering

with major

participants in the

fields of

antibiotics,

immuno-

modulators and

cancer.

1 2 3

4 5 6

7 8 9

Wide-scale Adoption

Glysantis leverages the vast potential of nanotherapy in

medicine by using safe, water-soluble, benign, mono-

disperse nanoparticles as the foundation for a wide

variety of new developments. Glysantis’ vision is to make

this inherently safe technology platform widely available

for drug development to improve the standard of care for

patients in wide areas of medicine, especially for patients

with severe or chronic diseases. The total market

potential in areas such as cancer treatment, antibiotics,

immunomodulators and imaging is above $100 billion.

Market Opportunity

NanoGlys-based antimicrobial therapeutic agents help to

fight infectious disease. In vitro immunomodulation

studies with Glysantis lead compounds showed

performance far above benchmark effects. In vitro

biodistribution studies using markers demonstrate

passive targeting of cancer tissue and also high affinity

to other tissues/organs.

NanoGlys particles created by nature in certain varieties of sweet

corn. Glysantis has found a way to preserve the natural particle

structure during the extraction and purification of this highly

monodisperse nano-material. The unique properties of this nano-

material make it an ideal platform for drug development, that is, it is

highly water soluble and non-toxic, biodegradable, and versatile. It

can be easily modified by standard methods in carbohydrate

chemistry (including the chemical attachment of drugs, biomarkers,

etc.) and is a “stealth carrier” as it is practically invisible to the

immune system.

Technology Profile

Phytoglycogen is hydrophilic, fully biodegradable and becomes a part of

the regular glucose metabolism when administered, which avoids

accumulation of the nano-carrier during treatment or residual nano-

material after therapy. In contrast to engineered nano-materials,

nanoglycogen and its metabolites do not exhibit safety or toxicity

problems. NanoGlys is just the right size for a highly effective drug

delivery system or application as a nano-probe. It has other advantages

such as a more favorable rate of biodegradation, as well as, better

selectivity and sensitivity. The material is inherently highly

monodisperse--an important feature in many biomedical applications.


Selective targeting and accumulation is a prime feature of drug

delivery carriers, as well as the release of the drug at its destination.

With liposomes, one of the FDA-approved nano-carriers, the drug

leaks from the nanoparticle in a time controlled manner. This

approach is limited to a small range of drugs and is not feasible for

biologics. NanoGlys particles use different pathways. Conjugates

have been shown to retain activity of the drug; the drug can be

anchored to NanoGlys with tethers that respond to external stimuli

or biodegradation of nanoglycogen, releasing the drug.

Competing Aspects

Glysantis’ main interest is preclinical development of the technology

platform. Glysantis’ business model is based on early stage licensing and

partnering with potential licensees. The company is reaching out to

other international research groups that have an interest in nano-sized

monodisperse carbohydrates. NanoGlys can be used for a wide range of

clinical indications. The main focus is on areas where the intrinsic

properties of native and modified nanoglycogen can be leveraged to

achieve unique effects, such as antibiotics, immunomodulation, and drug

delivery.


D951-TV


Glysantis believes the promise of

nanotechnology in medicine can yet be

fulfilled. Research on synthetic

nanomaterials has demonstrated the

potential for exciting therapeutic effects,

yet it has been limited by many inherent

problems with most nanomaterials. This

material provides what is needed to fulfil

this promise: a safe, water-soluble, and

modifiable nano-carrier.

Impact and Opportunities

Natural Monodisperse Phytoglycogen Nanomaterials for Advanced Drug Delivery

Glysantis, Inc.

8

Technology

Readiness Level

VECT-HORUS

plans to become

a major player in

the field of drug

and imaging

agent delivery,

especially in the

CNS. within the

next 5 years

1 2 3

4 5 6

7 8 9

Wide-scale Adoption

VECT-HORUS is also building a pipeline of

proprietary drug candidates for internal development

to reach preclinical or early clinical trials,

subsequently out-licensed to pharma/biotech

companies. VECT-HORUS’ lead compound, VH-

N439, a neuropeptide with global hypothermic

potential, is in regulatory preclinical studies. VH-N439

will be a first-in-class pharmacological agent inducing

therapeutic hypothermia and will be positioned as a

neuroprotective agent for sudden cardiac arrest

(SCA), neonatal ischemia, traumatic brain injury, and

potentially for stroke.

Market Opportunity

The CNS market is one of the largest and fastest

growing markets in the pharmaceutical industry. There is

a strong demand from the pharmaceutical industry for

innovative delivery strategies that could optimize drug

delivery across the BBB, and the potential market for

these technologies is growing rapidly. The market for

BBB technologies is expected to grow to $471.5 million

by 2019. Within this market, the technologies that use

RMT to carry molecules to the brain will represent most

of the growth and should generate sales of $456 million

by 2019. VECT-HORUS has set up various collaborative

programs to generate future revenues.

VECTrans® Technology Platform. This is focused on the

development of molecular vectors that facilitate the transport of drugs

and imaging/diagnostic agents to the brain. VECT-HORUS is focused

on drug delivery technologies to the brain and other tissues, including

tumors, and the development of innovative vectorized drugs and

imaging agents. The brain vascular system prevents the passage of

more than 98% of the drugs developed to date and is thus called the

blood-brain barrier (BBB).

Technology Profile

By combining pharmaceutical agents to its peptide-vectors designed to

target specific receptors, VECT-HORUS promotes delivery of these

agents to target cells or organs and allows them to cross natural

barriers such as the BBB, which significantly impedes brain delivery.

The transport of molecules by receptors (receptor mediated transport

or RMT) is now considered the most effective and safest way to

bypass the BBB. The highly specific and stable vectors identified and

validated by VECT-HORUS are protected by several families of

patents and patent applications.


The BBB excludes from the brain ~100% of large molecules (for

example, antibodies, proteins, peptides) and more than 98% of all

small-molecule drugs, thus representing a real technological barrier to

brain delivery of imaging agents and drugs developed to treat serious

brain diseases (Parkinson’s, multiple sclerosis, Alzheimer's, stroke,

and brain tumors). Therefore, methods that can enhance drug delivery

to the brain are of great interest.

Competing Aspects

VECT-HORUS’ business model is based on external (R&D contracts

with industrial partners) and internal (in-house pipeline development)

innovation strategies. VECT-HORUS’ mission is to make its highly

innovative VECTrans technological platform available to pharma and

biotech partners by transporting its drugs to the brain and other

organs. VECT-HORUS has granted non-exclusive licenses for its

vectors to industrial partners.


D951-TV


Sanofi will use VECT-HORUS’ proprietary

technology to transport therapeutic antibodies

into the brain for the treatment of a

neurodegenerative disease. Another

collaboration in the field of medical imaging is

focused on innovative nuclear/molecular

conjugates targeting the brain or other

organs/cancer tissues outside of the nervous

system. Recently, a collaboration agreement

was signed with Servier to transport a

therapeutic peptide into the brain for an

undisclosed indication.

Impact & Opportunities

Facilitating the Transport of Drugs and Imaging Agents via Molecular Vectors VECT-HORUS

"The agreements signed with our pharma partners reflects the growing interest in our drug delivery platform and validate the potential of our technology to facilitate the addressing of

diagnostic and therapeutic molecules to different organs and particularly to the brain”, says Dr Jamal TEMSAMANI, Director of Drug Development & Corporate of VECT-HORUS.

9

Technology Readiness

Level

Most patients prefer to take a drug orally

instead of getting an injection. However,

drugs made from large proteins cannot be

given as a pill as they would break up in

the stomach before they can be

absorbed. This capsule may potentially

serve as a novel technology platform for

the delivery of a broad spectrum of

therapeutics. This fact is specially

important in payload direction into the

lining of the gastrointestinal tract and

prevention of drug degradation.

Wide-scale Adoption

Many attempts to design

microparticles and nanoparticles to

deliver biologics have failed,

especially taking into account the

expensive cost and the need for re-

engineering the prototype for each

drug.

Market Opportunity

Coated with short needles, the product has

demonstrated safety. There are no pain

receptors in the gastrointestinal tract, so

patients would not feel any pain from the

drug injection. The pill would take at least a

week to move through the entire digestive

tract. This achievement is the result of tech

convergence.


The opportunities for this development are not

limited to diabetes care via insulin delivery.

Biopharmaceuticals such as antibodies for

immuno-oncology, including vaccines,

recombinant DNA and RNA can be successfully

delivered through this technology.


Novel drug capsule coated with tiny

needles that can inject drugs directly

into the lining of the stomach after the

capsule is swallowed. The research

was funded by the National Institutes of

Health.

Technology Profile

This insulin delivery system has

demonstrated more efficiency in animals

than subcutaneous injections and safety,

exhibiting no harmful side effects as the

capsule passed through the digestive

system.

Competing Aspects

The prototype consists of an acrylic capsule of 2

x 1 centimeters in length and diameter,

respectively, comprising a reservoir for the

drug. The capsule is coated with hollow,

stainless steel needles approximately 5

millimeters long.


2

1

3

4

5 6

7

8

9

D951-TV

Microneedle Pill with Hollow Needles Massachusetts Institute of Technology (MIT) – Massachusetts General Hospital (MGH)

10


Level

As these liposomes resulted in no or

negligible reaction in blood serum of pigs,

it is expected that the researchers will be

able to achieve similar results in human

bodies too. However, there is a long way

to go before this research initiative will be

clinically evaluated in human adults.

Wide-scale adoption is only expected

upon completion of exhaustive pre-clinical

tests and human clinical trials.

Wide-scale Adoption

According to World health Organization

(WHO), coronary artery disease results in

an estimated 30% of the deaths worldwide

and there is a huge demand for medication

that can efficiently cover pre-hospital

medical aid, that is, before the patient is

transported to the hospital for surgical

treatment.

Market Opportunity

Liposomes in drug delivery have found

widespread acceptance in the last decade

as they are capable of targeted delivery and

embedding the drug molecules inside their

water-filled cavity allows for efficient

transport of the drug. The convergence of

nanotechnology, biology, and medicine is

important and can be used to treat a

number of other coronary heart ailments.


The opportunities of this development are not

limited to treatment of coronary artery disease

but can be extended to a number of medical

applications where immune response is

unfavorable, especially in gene therapy and

organ transplants.


Liposomes are commonly used as drug

delivery vehicles to transport drugs to

various organs in the human body.

However, since they are identified as

foreign substances by the immune system

in the body, the activation of immune

response leads to pseudo-allergy that can

lead to harmful anaphylactic shocks.

Technology Profile

The research team at the University of

Basel has developed artificial liposomal

vesicles in a lenticular form for drug

delivery to constricted coronary arteries.

However, the major competing aspect is

the fact that these artificial vesicles do not

elicit any immune response in the human

body and are completely ignored by the

immune system.

Competing Aspects

Artificial phospholipid vesicles (Pad-PC-Pad vesicles)

were injected in three Yorkshire pigs and their heart

rate, electrocardiogram (ECG) and blood pressure

was monitored. High doses of these vesicles resulted

in negligible reactions and no toxic changes in

kidneys, lungs, heart, and liver were noticed in tissue

biopsies.


2

1

3

4

5 6

7

8

9

D951-TV

New Liposomal Vesicles to Help Treat Coronary Artery Disease The University of Basel

11


Level

The company has so far tested the

NanoJackets with a host of

pharmaceutical therapies in cells and

human cancer models (in vitro) and has

received satisfactory results. Further

clinical testing is required before the

company can file for regulatory approvals

in the respective regions. Wide-scale

adoption of the technology is expected by

2020.

Wide-scale Adoption

Targeted cancer therapies hold a major

share in the total cancer therapy market.

Many pharmaceutical and biotechnology

companies are drawn by the continuous

success of targeted cancer therapies. The

technology developed by Keystone Nano

has huge potential in this market.

Market Opportunity

The NanoJacket technology being

developed by Keystone Nano can be used

to transform liver, pancreatic and breast

cancer treatment with fewer side-effects.

Through size and surface change, a wide

range of targeting materials can be

attached to the surface and used for other

applications.


Keystone Nano is currently commercializing

NanoJacket products and Ceramide

NanoLiposome for a number of medical

applications. With 14 issued patents and 8

pending patents, the product pipeline of the

company is expected to cater to cancer therapy

needs.


Targeted cancer therapies have found

widespread coverage in the last decade

owing to its capability to treat various

tumors in the human body. The

conventional methods of tumor therapy

include radio and chemotherapy and they

are extremely dangerous for the

surrounding healthy tissues.

Technology Profile

The company has developed the

NanoJacket technology that is a novel

biocompatible, composite nanoparticle

technology with the ability to improve the

effectiveness of cancer therapies. The

NanoJacket technology has the ability to

load both hydrophilic and hydrophobic

compounds as active ingredients.

Competing Aspects

To improve biocompatibility and acceptance with the

immune system, the NanoJackets are made up of

calcium, phosphate, and silicates that occur naturally

in the body. With a size of 5-50 nanometers,

NanoJacket particles can circulate well in blood and

enter tumor cells to destroy them. The active

pharmaceutical ingredients are stored inside

NanoJackets that prevent degradation of the drug

during circulation.


2

1

3

4

5 6

7

8

9

D951-TV

Biocompatible Targeted Cancer Therapy Keystone Nano, Inc.

12


Level

With enhanced delivery over topical

administration routes, the FluidCrystal

nanoparticle technology holds

promise and the company is currently

developing a range of products based

on it. As the products are still in the

clinical trial stages and require

regulatory review, wide-scale

adoption is expected toward the end

of 2019.

Wide-scale Adoption

The global drug delivery market is a multi-

billion dollar market that has witnessed a

huge change in delivery formulations in the

last decade. The novel nanoparticle-based

technology from the company has huge

potential to disrupt the way drugs are

delivered inside the human body.

Market Opportunity

Camurus’ technology addresses a number

of unmet medical needs. The company is

developing products to treat a range of

therapeutic areas such as cancer, chronic

pain, opioid dependence, endocrinology

and other disease areas. All these products

are in different development stages

currently.


Camurus has partnered with a number of firms in

the biotech space to promote clinical trials of its

existing products. One of the key partnerships

has been with Braeburn Pharmaceuticals, a

company delivering precision medicine, to initiate

Phase III trial of its opioid dependence treatment

drug. Ultimately, Camurus is expected to

leverage this partnership to commercialize its

product once it receives regulatory approvals.


Amphiphilic drugs and lipophilic drugs often face

bioavailability issues once they are administered

to the human body as they often lose their

strength after passing through the Gastro-

intestinal (GI) tract in the human body. As a

result, less than half the quantity of the drug is

made available at the desired site in the body.

The FluidCrystal nanoparticles technology has

been developed to address these bioavailability

limitations.

Technology Profile

The FluidCrystal technology has been

developed by the company to increase

bioavailability of lipophilic drugs that have low

aqueous solubility and also for biodegradation-

sensitive drugs, especially proteins and

peptides, that are difficult to transport across cell

membranes otherwise.

Competing Aspects

FluidCrystal nanoparticles are water-based

substances and consist of a stable emulsion of

nanoparticles that have a liquid crystalline

structure. Products based on this technology

enhance systemic circulation of the drugs and are

preformed to stable dispersions that can be

applied to the skin or mucous membranes in the

spray form or injected intravenously or

subcutaneously or through an intramuscular or

intracavital injection.


2

1

3

4

5 6

7

8

9

D951-TV

Nanoparticle-Based Technology to Improve Drug Bioavailability Camurus AB

13 D951-TV

Appendix

14

Title Publication

Date/Publication

Number

Assignee Abstract

Drug delivery device with

means for disabling

activation of expelling

mechanism

31.03.2016/

US20160089500

Novo Nordisk

A/S

A drug delivery device has a cartridge holder adapted to receive and hold a

cartridge, the cartridge holder having a receiving and a holding state. The device

further comprises a drive assembly with a piston rod and a drive spring, setting

means allowing a user to set a dose amount to be expelled and strain the drive

spring correspondingly, and user actuated release means for releasing the drive

spring, wherein the drive assembly spring cannot be released to move the piston rod

unless the cartridge holder is in the holding state.

Drug delivery device

including electrolytic

pump

31.03.2016/

US20160089490

King Abdullah

University of

Science and

Technology

Ian G. FouldsSystems and methods are provided for a drug delivery device and use

of the device for drug delivery. In various aspects, the drug delivery device combines

a “solid drug in reservoir” (SDR) system with an electrolytic pump. In various

aspects an improved electrolytic pump is provided including, in particular, an

improved electrolytic pump for use with a drug delivery device, for example an

implantable drug delivery device. A catalytic reformer can be incorporated in a

periodically pulsed electrolytic pump to provide stable pumping performance and

reduced actuation cycle.

Patents related to Picture Credit: Frost & Sullivan; WIPO Database

Drug delivery primarily refers to transporting a pharmaceutical compound, usually a drug, in to provide the therapeutic effect required by

the body. A number of medical devices or drug delivery devices have been developed for this purpose which deliver the formulation at

the required site. Drug delivery systems are extremely crucial to deliver drugs to the human body especially for people who require drugs

at regular intervals, such as diabetics requiring doses of insulin. Targeted delivery is one of the most recent trends associated with drug

delivery technologies. In targeted delivery, the drug or the pharmaceutical formulation is only active at the target site and does not affect

the surrounding tissues in the human body. One of the most researched areas of targeted delivery includes pharmaceutical compositions

targeted at cancerous tissues in the human body. Targeted delivery ensures that none of the surrounding healthy tissue is affected as a

result. Drug carriers form an essential aspect of drug delivery systems, as they are expected to enhance the bioavailability of the drug in

the human body as well as provide stability and solubility to the drug to help initiate its mode of action.

D950-TV

Patents Related to Novel Drug Delivery Systems

15

Title Publication

Date/Publication

Number

Assignee Abstract

Nanoporous micro-

spherical polyimide

aerogels and method for

preparing same

31.03.2016/

WO/2016/047821

Industry-Academic

Cooperation

Foundation,

Yonsei University

The present invention relates to nanoporous micro-spherical polyimide

aerogels and a method for preparing the same. The use of the method for

preparing polyimide aerogels, according to an embodiment of the present

invention, enables the preparation of the polyimide aerogels through a low-

temperature process, and thus can save energy and time when compared

with existing preparing methods, can reduce production costs, and can

prepare spherical polyimide aerogels, which are micro-sized uniform

particles, having excellent chemical stability, thermal insulation

characteristics, and absorption-desorption characteristics while having nano-

sized pores. The spherical polyimide aerogels can be applied to various

fields, such as an insulator, a drug delivery medium, and a catalyst supporter,

due to excellent physical properties thereof.

Vibration sensor based

drug delivery monitor

31.03.2016/

WO/2016/049066

Oscillari LLC A monitoring system comprising a monitor that utilizes a vibration sensor to

monitor the occurrence and properties of events. The monitor does not

require disassembly of the device to be monitored, or interfere with operation

of the device monitored and maybe affixed to the exterior of a device to be

monitored or a component thereof, or be integrated into the design of the

device. The device to be monitored may be a drug delivery device such as an

inhaler or autoinjector. The monitoring system includes a display device such

as a smartphone or tablet computer for analyzing data related to the device to

be monitored usage and displaying information to a user, patient and/or

caregiver before, during, and after a usage event such as the inhalation flow

rate through an inhaler, and the dose delivered by an injector.

Picture Credit: Frost & Sullivan; WIPO Database

D950-TV


16

Title Publication

Date/Publication

Number

Assignee Abstract

Devices and methods for

delivering a beneficial

agent to a user

31.03.2016/

WO/2016/049224

Abbvie Inc. Drug delivery reservoir for delivery of a beneficial agent to a user includes a

drug delivery reservoir housing (10) having a fluid reservoir (12) defined

therein. The drug delivery reservoir housing (10) has a drug delivery reservoir

base region (83). The drug delivery reservoir includes a dip tube (13) extending

inside the fluid reservoir. The dip tube (13) includes a tubular wall defining a

flow lumen. The tubular wall has at least one aperture (14) defined therein and

spaced proximally from a distal end of the tubular wall in fluid communication

with the fluid reservoir. The drug delivery reservoir includes an adaptor (15)

disposed external to the drug delivery reservoir housing (10) and coupled to a

proximal end of the dip tube.

Metal embedded

hydrophilic polymer for

drug delivery applications

31.03.2016/

WO/2016/046847

Council of

Scientific &

Industrial

Research

The present invention discloses a porous polymer for drug delivery application

comprising poly(acrylic acid-co-trimethylolpropane triacrylate) supported gold

or poly(methacrylic acid- co-pentaerythritol triacrylate) supported silver/copper

for controlled and selective in vitro drug delivery.

Picture Credit: Frost & Sullivan; WIPO Database

D950-TV


17

Industry Interactions

Chief Executive Officer,

Glysantis Inc.,

Canada

Phone: +1-905-339-9907

E-mail: [email protected]

Phil Whiting

Postdoctoral Fellow and Entrepreneur,

Massachusetts Institute of Technology,

77 Massachusetts Avenue Cambridge, MA 02139-

4307.

Phone: +617-253-3107

Fax: +617-258-8827


URL: https://dbgroup.mit.edu/carl-schoellhammer

President,

Glysantis Inc.,

361 Southgate Drive - Unit C, Guelph,

Ontario N1G 3M5, Canada.

Phone: +1-919-923-2159.


URL: http://www.glysantis.com/

Thomas Engelhardt

Head of Business Development and

Commercial Operations, BIOCORP.

Parc Technologique Lavaur-la-

Béchade, 63500 Issoire, France.

Phone : +33-6-08-02-14-51

Fax : +33-4-73-55-01-86


URL: http://www.biocorp.fr/

Eric Dessertenne

PhD, Director of Drug Development and

Corporate, VECT-HORUS,

Faculté de Médecine, Secteur Nord, CS80011,

51, Bd Pierre Dramard, 13344 - Marseille

Cedex 15, France.

Phone: +33-4-91-69-87-81


URL: http://www.vect-horus.com/

Jamal Temsamani, PhD

Carl Schoellhammer

D951-TV

mailto:[email protected]


https://dbgroup.mit.edu/carl-schoellhammer





http://www.glysantis.com/

http://www.glysantis.com/


http://www.biocorp.fr/

http://www.biocorp.fr/




http://www.vect-horus.com/




18

Industry Interactions

President & Chief Executive Officer,

Camurus AB,

Ideon Science Park,

SE-223 70 Lund, Sweden

Phone: +46-46-286-46-92


URL: http://www.camurus.com/home/

Fredrik Tiberg

Chief Executive Officer,

Keystone Nano, Inc.,

1981 Pine Hall Rd,

State College PA 16801.

Phone: +1-814-237-4657


URL: http://www.keystonenano.com/

Jeff Davidson

D951-TV

Professor,

Biomaterials Science Center,

University of Basel,

Gewerbestrasse 14,

4123 Allschwil, Switzerland

Phone: +41-61-265-9660


URL: https://bmc.unibas.ch/institute/bert_mueller.phtml

Bert Müller


http://www.camurus.com/home/

http://www.camurus.com/home/


http://www.keystonenano.com/

http://www.keystonenano.com/


https://bmc.unibas.ch/institute/bert_mueller.phtml

https://bmc.unibas.ch/institute/bert_mueller.phtml

drug discovery alert (techvision) - frost & sullivan · to achieve an in-depth understanding...

Documents